Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 6,435 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin to Skin Clear all
Completed No phase listed Observational Accepts healthy volunteers

Histology of Functional Density in Postmenopausal Breast

NCT01240278
View directory record Official record
Conditions
Dense Breasts, Breast Cancer
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

A Safety Study of SGN-LIV1A in Breast Cancer Patients

NCT01969643
View directory record Official record
Conditions
HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Triple Negative Breast Neoplasms, HER2 Mutations Breast Neoplasms
Interventions
ladiratuzumab vedotin, Trastuzumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
38
States / cities
Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 24, 2026, 8:14 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

NCT05232916
View directory record Official record
Conditions
Breast Cancer
Interventions
Placebo, GLSI-100
Biological
Lead sponsor
Greenwich LifeSciences, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
51
States / cities
Mobile, Alabama • Goodyear, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

A Phase II Study in Patients With Alopecia Areata

NCT04346316
View directory record Official record
Conditions
Alopecia Areata
Interventions
SHR0302
Drug
Lead sponsor
Reistone Biopharma Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Northridge, California • Brandon, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility Study: Evaluate the Effectiveness of Using a Topical Anesthetic Prior to Ultherapy™ Treatment

NCT01708447
View directory record Official record
Conditions
Skin Laxity
Interventions
L.M.X.4.® cream, A placebo cream, Ulthera System Treatment
Drug · Other · Device
Lead sponsor
Ulthera, Inc
Industry
Eligibility
30 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

NCT01709578
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, placebo, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
56
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Not applicable Interventional Results available

AMNIOEXCEL® Plus vs A Marketed Comparator vs SOC in the Management of Diabetic Foot Ulcers

NCT03547635
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
AMNIOEXCEL Plus Amniotic Membrane, A Marketed Comparator, Standard of Care
Other · Device
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
21 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Fresno, California • Los Angeles, California • Gainesville, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 24, 2026, 8:14 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy

NCT03750240
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Sodium (Na) Magnetic Resonance Imaging (MRI), Dynamic Contrast- Enhanced (DCE) MRI
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Not applicable Interventional Results available

Impact of Skin to Skin Contact on Maternal Satisfaction, Pain Scores, and Narcotic Usage After Cesarean Delivery

NCT02533167
View directory record Official record
Conditions
Skin to Skin Contact in Cesarean Deliveries
Interventions
skin to skin
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

NCT02852967
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Belumosudil, Placebo
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
14
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 24, 2026, 8:14 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Cancer Experience Registry (CER) for Cancer Patients and Caregivers

NCT02333604
View directory record Official record
Conditions
Neoplasms, Cancer, Caregiver
Interventions
Not listed
Lead sponsor
Cancer Support Community, Research and Training Institute, Philadelphia
Other
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2035
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Not applicable Interventional

Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors

NCT02150148
View directory record Official record
Conditions
Cancer
Interventions
Experimental: Mentored Gardening Intervention
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

NCT02586987
View directory record Official record
Conditions
Lung Cancer, Melanoma, Head and Neck Carcinoma, Gastroesophageal Cancer, Breast Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Biliary Tract Cancer
Interventions
Selumetinib, MEDI4736, Tremelimumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 24, 2026, 8:14 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma

NCT02186249
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
U.S. locations
57
States / cities
Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2017 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Not applicable Interventional Results available

CCCR Lupus Patient Navigator Program

NCT04461158
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Patient Navigator Services
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin

NCT00907426
View directory record Official record
Conditions
Hypotrichosis
Interventions
Bimatoprost 0.03% solution, Vehicle solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept

NCT01901185
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis
Interventions
Etanercept / Autoinjector A
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
13
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Riociguat in Scleroderma Associated Digital Ulcers

NCT02915835
View directory record Official record
Conditions
Scleroderma, Digital Ulcers
Interventions
Riociguat, Placebo
Drug
Lead sponsor
Dinesh Khanna, MD, MS
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue

NCT03220893
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Digital Breast Tomosynthesis (DBT), Scintimammography
Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
3,023 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
5
States / cities
Detroit, Michigan • Rochester, Minnesota • Toledo, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Feasibility of One-Step Sentinel Lymph Node (SLN) Biopsy With Radiolabeled Methylene Blue (IND 70,627)

NCT00784849
View directory record Official record
Conditions
Breast Cancer
Interventions
Methylene blue
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
2
States / cities
Lafayette, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 1 Interventional Results available

Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis

NCT04975438
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
GSK1070806, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
North Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Not applicable Interventional

Evaluation of the Efficacy of National Cancer Institute's Facing Forward Booklet in the Cancer Community Setting

NCT01440855
View directory record Official record
Conditions
Prostate Cancer, Breast Cancer, Colorectal Cancer, Thoracic Cancer
Interventions
CIS (Cancer Information Service) Information Sheet, Facing Forward booklet
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

NCT00954226
View directory record Official record
Conditions
Recurrent Head and Neck Carcinoma, Recurrent Salivary Gland Carcinoma, Recurrent Skin Carcinoma, Skin Squamous Cell Carcinoma
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 24, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

Evaluate the Effect of Elimune Capsules

NCT02251678
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Elimune Capsules
Dietary Supplement
Lead sponsor
Elorac, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Chicago, Illinois • Lake Forest, Illinois • Fair Lawn, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 24, 2026, 8:14 PM EDT